China’s AI drug discovery platform StoneWise bags $100m in Series B, B+ rounds
StoneWise, a Chinese pharmaceutical firm that uses AI to accelerate the development of new drugs, has received an aggregate of $100 million in its Series B and B+ rounds of financing, it announced on Monday.
Create an account to continue reading our free content.
Already have an account? Sign in here
Bring stories like this into your inbox every day.
Sign up for our newsletter – The Daily Brief
Related Stories
By far, the firm has served over 70 drugmakers across markets such as the US, Europe, China and Japan.
The fund will invest in semiconductors, new energy vehicles, and consumer electronics, among other sectors.
